• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

Professional Introduction to 6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic Acid (CAS No. 1041853-22-8)

6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid, identified by its CAS number 1041853-22-8, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the cinnoline family, which is known for its diverse biological activities and potential applications in drug development. The unique structural features of 6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid, including its bromine and ethoxy substituents, as well as its hydroxyl group, make it a valuable scaffold for further chemical modifications and biological evaluations.

The significance of 6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid lies in its potential as a precursor in the synthesis of more complex molecules with therapeutic properties. Researchers have been exploring its utility in the development of novel compounds that target various diseases, particularly those involving abnormal cell proliferation and inflammation. The bromine atom in the molecule provides a reactive site for cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings, which are widely used in the construction of biaryl structures. These types of structures are prevalent in many pharmacologically active agents.

In recent years, there has been a surge in interest regarding the use of heterocyclic compounds like cinnolines in medicinal chemistry. The< strong>cinnoline core has been extensively studied for its antimicrobial, anti-inflammatory, and anticancer properties. Specifically, derivatives of cinnoline have shown promise in inhibiting kinases and other enzymes involved in cancer pathways. For instance, studies have demonstrated that certain cinnoline-based compounds can modulate the activity of tyrosine kinases, which are critical in signal transduction pathways that drive cell growth and survival.

The< strong>ethoxy group present in 6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid contributes to its pharmacological profile by influencing both solubility and metabolic stability. Ethoxy-substituted compounds often exhibit improved bioavailability and reduced toxicity compared to their unsubstituted counterparts. This feature makes 6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid an attractive candidate for further development into a lead compound for drug discovery programs.

The< strong>hydroxyl group at the 4-position of the cinnoline ring adds another layer of reactivity to the molecule. Hydroxyl groups are known to participate in hydrogen bonding interactions, which can be crucial for binding affinity and selectivity when designing small molecule drugs. Additionally, the hydroxyl group can be further functionalized through oxidation or esterification reactions, expanding the synthetic possibilities for generating diverse derivatives.

In the context of current research, 6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid has been investigated for its potential role in addressing neurological disorders. Preliminary studies suggest that cinnoline derivatives may interact with specific neurotransmitter receptors or ion channels, potentially offering therapeutic benefits in conditions such as Alzheimer's disease and Parkinson's disease. The< strong>bromine substituent, while primarily serving as a handle for synthetic transformations, may also contribute to the compound's ability to cross the blood-brain barrier, enhancing its bioavailability.

The synthesis of< strong>6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid involves multi-step organic reactions that require careful optimization to achieve high yields and purity. Common synthetic routes include cyclization reactions followed by functional group interconversions. The use of palladium catalysts in cross-coupling reactions is particularly relevant here, as these reactions allow for the introduction or manipulation of bromine-containing moieties efficiently.

Evaluation of< strong>6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid's biological activity has been conducted using both in vitro and in vivo models. In cell-based assays, this compound has shown promise in inhibiting the proliferation of certain cancer cell lines by disrupting key signaling pathways. Additionally, animal models have provided insights into its potential therapeutic effects without significant off-target toxicities. These findings underscore the importance of< strong>cinnoline derivatives as viable candidates for further clinical investigation.

The future direction of research involving< strong>6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid may include structure-based drug design approaches, where computational modeling techniques are used to understand molecular interactions at an atomic level. This approach can guide the optimization process by predicting how structural modifications will affect biological activity. Furthermore, exploring new synthetic methodologies that enhance efficiency and sustainability will be crucial for scaling up production while maintaining cost-effectiveness.

In conclusion,< strong>6-bromo-7-ethoxy-4-hydroxycinnoline carboxylic acid (CAS No. 1041853)] represents a promising compound with diverse applications in pharmaceutical research. Its unique structural features make it a versatile scaffold for developing novel therapeutic agents targeting various diseases. As research continues to uncover new biological functions and synthetic strategies, this compound is poised to play an important role in advancing drug discovery efforts worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)